<DOC>
	<DOCNO>NCT02879981</DOCNO>
	<brief_summary>This pilot , multicentric observational study ass safety sulfamethoxazole + trimethoprim + guaifenesin ( Balsamic Bactrim ) pediatric participant acute bronchitis . Administration treatment accord physician 's recommendation local labeling .</brief_summary>
	<brief_title>A Safety Study Balsamic Bactrim Pediatric Participants With Acute Bronchitis</brief_title>
	<detailed_description />
	<mesh_term>Bronchitis</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<mesh_term>Sulfamethoxazole</mesh_term>
	<mesh_term>Trimethoprim</mesh_term>
	<mesh_term>Trimethoprim , Sulfamethoxazole Drug Combination</mesh_term>
	<mesh_term>Guaifenesin</mesh_term>
	<mesh_term>Phenylpropanolamine</mesh_term>
	<mesh_term>Chlorpheniramine , phenylpropanolamine drug combination</mesh_term>
	<criteria>Participants start treatment Bactrim Balsamic suspension Participants clinical diagnosis acute bronchitis accord pulmonologist clinical criterion Participants start treatment another antibiotic time visit Participants respiratory infection Participants mental disorder Participants severe hepatic parenchymal damage Participants severe renal failure make difficult monitor drug plasma concentration Participants hypersensitivity Balsamic Bactrim active ingredient excipients</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>